Other TAVs frequently used in pancreatic cancer clinical trials include CRS-207 (live-attenuated Listeria monocytogenes expressing human mesothelin) and recombinant peptide vaccines that are listed in Table 4 (NCT03190265, NCT02004262, and NCT01417000) [96,97,98]. This evidence concerns the gene MSLN and familial pancreatic carcinoma.